Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Phase 1
Not yet recruiting
Conditions
Lymphoma, T-Cell
Interventions
Drug: GCC2005
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2024-11-21
Last Posted Date
2024-11-25
Lead Sponsor
GC Cell Corporation
Target Recruit Count
48
Registration Number
NCT06699771
Locations
🇰🇷

Seoul National University Hosptial, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
18
Registration Number
NCT06696833
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu, China

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

First Posted Date
2024-11-15
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT06690281
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Study of ARD103 CAR-T Therapy for Patients with R/R AML or MDS

First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
ARCE Therapeutics, Inc.
Target Recruit Count
49
Registration Number
NCT06680752

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Leland Metheny
Target Recruit Count
20
Registration Number
NCT06680661
Locations
🇺🇸

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

First Posted Date
2024-11-07
Last Posted Date
2024-11-07
Lead Sponsor
Indapta Therapeutics, INC.
Target Recruit Count
34
Registration Number
NCT06677710
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States

🇺🇸

Stanford University, Stanford, California, United States

and more 1 locations

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

First Posted Date
2024-10-28
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
39
Registration Number
NCT06660420
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

First Posted Date
2024-10-24
Last Posted Date
2024-10-24
Lead Sponsor
Renmin Hospital of Wuhan University
Target Recruit Count
15
Registration Number
NCT06656962
Locations
🇨🇳

Renmin hospital of Wuhan University, Wuhan, Hubei, China

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

First Posted Date
2024-10-18
Last Posted Date
2024-12-05
Lead Sponsor
Children's Oncology Group
Target Recruit Count
110
Registration Number
NCT06647953

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

First Posted Date
2024-10-15
Last Posted Date
2024-11-05
Lead Sponsor
Essen Biotech
Target Recruit Count
85
Registration Number
NCT06640582
Locations
🇨🇳

District One Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy